Lipoprotein(a) testing remains infrequent in U.S. health systems, highlighting a need for improved provider and patient education as new targeted therapies emerge.
Lp(a) testing is relatively infrequent in health systems across the U.S. As new therapies for Lp(a) emerge, improved patient and provider education is needed to increase awareness of the utility of this risk marker.
Kelsey et al. (Wed,) studied this question.